These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 15753455

  • 1. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Wong ET.
    Neurology; 2005 Mar 08; 64(5):934; author reply 934. PubMed ID: 15753455
    [No Abstract] [Full Text] [Related]

  • 2. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Wong ET, Tishler R, Barron L, Wu JK.
    Cancer; 2004 Jul 01; 101(1):139-45. PubMed ID: 15221999
    [Abstract] [Full Text] [Related]

  • 3. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
    Pitini V, Arrigo C, Righi M.
    Cancer; 2004 Dec 15; 101(12):2900-1; author reply 2901-2. PubMed ID: 15529311
    [No Abstract] [Full Text] [Related]

  • 4. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
    Doolittle ND, Anderson CP, Bleyer WA, Cairncross JG, Cloughesy T, Eck SL, Guastadisegni P, Hall WA, Muldoon LL, Patel SJ, Peereboom D, Siegal T, Neuwelt EA.
    Neuro Oncol; 2001 Jan 15; 3(1):46-54. PubMed ID: 11305417
    [Abstract] [Full Text] [Related]

  • 5. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
    Enting RH, Demopoulos A, DeAngelis LM, Abrey LE.
    Neurology; 2004 Sep 14; 63(5):901-3. PubMed ID: 15365145
    [Abstract] [Full Text] [Related]

  • 6. Rituximab maintenance therapy in central nervous system lymphoma?
    Murawski N, Pfreundschuh M.
    Leuk Lymphoma; 2009 Oct 14; 50(10):1555-6. PubMed ID: 19757314
    [No Abstract] [Full Text] [Related]

  • 7. Temozolomide as salvage treatment in primary brain lymphomas.
    Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri AJ.
    Br J Cancer; 2007 Mar 26; 96(6):864-7. PubMed ID: 17325700
    [Abstract] [Full Text] [Related]

  • 8. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.
    Santisteban M, Nieto Y, De la Cruz S, Aristu J, Zubieta JL, Fernández Hidalgo O.
    Clin Transl Oncol; 2007 Jul 26; 9(7):465-7. PubMed ID: 17652061
    [Abstract] [Full Text] [Related]

  • 9. Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.
    Nayak L, Abrey LE, Drappatz J, Gilbert MR, Reardon DA, Wen PY, Prados M, Deangelis LM, Omuro A, North American Brain Tumor Consortium.
    Leuk Lymphoma; 2013 Jan 26; 54(1):58-61. PubMed ID: 22656234
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Central nervous system glioma. Multi-drug chemotherapy including temozolomide].
    Wakabayashi T.
    Gan To Kagaku Ryoho; 2009 Jun 26; 36(6):938-40. PubMed ID: 19579330
    [No Abstract] [Full Text] [Related]

  • 13. Phase II trial of temozolomide plus concurrent whole-brain radiation followed by TNV regimen as adjuvant therapy for patients with newly diagnosed primary CNS lymphoma.
    Wang Y, Liu B, Xu D, Zhao H, Zhu Y, Xu J, Tao R.
    Neurol India; 2013 Jun 26; 61(3):260-4. PubMed ID: 23860145
    [Abstract] [Full Text] [Related]

  • 14. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
    Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S, 415 study investigators.
    Br J Haematol; 2013 Nov 26; 163(3):334-42. PubMed ID: 24032456
    [Abstract] [Full Text] [Related]

  • 15. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
    Baruchel S, Diezi M, Hargrave D, Stempak D, Gammon J, Moghrabi A, Coppes MJ, Fernandez CV, Bouffet E.
    Eur J Cancer; 2006 Sep 26; 42(14):2335-42. PubMed ID: 16899365
    [Abstract] [Full Text] [Related]

  • 16. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
    Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D.
    Br J Cancer; 1999 Nov 26; 81(6):1022-30. PubMed ID: 10576660
    [Abstract] [Full Text] [Related]

  • 17. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
    Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J.
    Cancer Chemother Pharmacol; 2008 May 26; 61(6):1059-67. PubMed ID: 17694310
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Combination therapy with rituximab and temozolomide for recurrent and refractory primary central nervous system lymphoma.
    Murakami M, Fujimaki T, Asano S, Nakaguchi H, Yamada SM, Hoya K, Yamazaki K, Ishida Y, Matsuno A.
    Yonsei Med J; 2011 Nov 26; 52(6):1031-4. PubMed ID: 22028172
    [Abstract] [Full Text] [Related]

  • 20. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature.
    Pels H, Schulz H, Schlegel U, Engert A.
    Onkologie; 2003 Aug 26; 26(4):351-4. PubMed ID: 12972702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.